Neulasta Biosimilar: Smooth Patent Dance, Stumble On Launch Notification
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen patent infringement suit follows information exchange with Apotex; Federal Circuit’s ruling on commercial notification to be tested.